Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis
M Brunström, B Carlberg - JAMA internal medicine, 2018 - jamanetwork.com
Importance High blood pressure (BP) is the most important risk factor for death and
cardiovascular disease (CVD) worldwide. The optimal cutoff for treatment of high BP is …
cardiovascular disease (CVD) worldwide. The optimal cutoff for treatment of high BP is …
[HTML][HTML] A'diamond'approach to personalized treatment of angina
In clinical guidelines, drugs for symptomatic angina are classified as being first choice (β-
blockers, calcium-channel blockers, short-acting nitrates) or second choice (ivabradine …
blockers, calcium-channel blockers, short-acting nitrates) or second choice (ivabradine …
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of …
Surveys and registries are needed to verify that real-life daily practice is in keeping with what
is recommended in the guidelines, thus completing the loop between clinical research …
is recommended in the guidelines, thus completing the loop between clinical research …
[PDF][PDF] 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
Podstawą uaktualnień dotyczących postępowania u pacjentów z zawałem serca z
uniesieniem odcinka ST (STEMI) powinny być rzetelne dowody, pochodzące w miarę …
uniesieniem odcinka ST (STEMI) powinny być rzetelne dowody, pochodzące w miarę …
Treatment of angina: where are we?
C Balla, R Pavasini, R Ferrari - Cardiology, 2018 - karger.com
Ischaemic heart disease is a major cause of death and disability worldwide, while angina
represents its most common symptom. It is estimated that approximately 9 million patients in …
represents its most common symptom. It is estimated that approximately 9 million patients in …
Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14–effects of different classes of antihypertensive drugs in older and younger …
C Thomopoulos, G Parati, A Zanchetti - Journal of hypertension, 2018 - journals.lww.com
Methods: Two databases we had previously identified [72 placebo-controlled BP-lowering
randomized clinical trials (RCTs) in 260 210 individuals and 50 RCTs head-to-head …
randomized clinical trials (RCTs) in 260 210 individuals and 50 RCTs head-to-head …
Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 13–benefits and adverse events in older and younger patients with …
C Thomopoulos, G Parati, A Zanchetti - Journal of hypertension, 2018 - journals.lww.com
Background: There is overwhelming evidence that blood pressure (BP)-lowering treatment
can reduce cardiovascular outcomes also in the elderly, but some important aspects …
can reduce cardiovascular outcomes also in the elderly, but some important aspects …
Дислипидемии, атеросклероз и ишемическая болезнь сердца: современные аспекты патогенеза, диагностики и лечения
ИВ Сергиенко, АА Аншелес, ВВ Кухарчук - 2018 - elibrary.ru
В третье издание монографии, посвященной атеросклерозу, вошла предыдущая книга
авторов «Атеросклероз и дислипидемии», выпущенная в 2017 г., а также новые главы …
авторов «Атеросклероз и дислипидемии», выпущенная в 2017 г., а также новые главы …
Blood pressure-lowering drugs and secondary prevention of cardiovascular disease: systematic review and meta-analysis
Objective: To systematically evaluate the efficacy of five commonly used blood pressure-
lowering drugs in reducing cardiovascular events among patients with nonacute …
lowering drugs in reducing cardiovascular events among patients with nonacute …
Cost-effectiveness analysis of bariatric surgery for morbid obesity in Belgium
O Borisenko, V Lukyanov, I Debergh… - Journal of medical …, 2018 - Taylor & Francis
Aims: This study presents the cost-effectiveness analysis of bariatric surgery in Belgium from
a third-party payer perspective for a lifetime and 10-year horizon. Materials and methods: A …
a third-party payer perspective for a lifetime and 10-year horizon. Materials and methods: A …